Yasky J, Ledesma G A, Tutera A, Collia L F
Pharmatherapeutica. 1986;4(8):480-5.
Seventeen non-digitalized congestive heart failure patients were treated with only the fixed-dose combinations of 20 mg furosemide and 50 mg spironolactone or 20 mg furosemide and 100 mg spironolactone, in a daily dose of 1 or 2 capsules, over a 4-week period. The selected patients had a severity rating ranging between Grades III and IV. Ten of these patients had a severe grade of dyspnoea. Assessments were made on the basis of the reduction in cardiac failure score, extent of reduction in oedema, and relief of dyspnoea. Safety variables measured included laboratory, echocardiographic and side-effect monitoring. By the end of the 4-week study period, significant reduction (46% to 51%) in cardiac score and complete relief of dyspnoea with no adverse effects on safety variables were recorded. These results indicate that it is possible to treat patients with congestive heart failure safely with the fixed-dose combination product without the concurrent use of digitalis.
17名未使用洋地黄的充血性心力衰竭患者接受了为期4周的治疗，仅服用固定剂量组合的药物，即每日1或2粒胶囊，其中包含20毫克呋塞米和50毫克螺内酯或20毫克呋塞米和100毫克螺内酯。所选患者的严重程度评级在III级至IV级之间。其中10名患者有严重的呼吸困难。评估基于心力衰竭评分的降低、水肿减轻程度和呼吸困难缓解情况。测量的安全变量包括实验室检查、超声心动图检查和副作用监测。在4周的研究期结束时，记录到心脏评分显著降低（46%至51%），呼吸困难完全缓解，且对安全变量无不良影响。这些结果表明，使用固定剂量组合产品可以安全地治疗充血性心力衰竭患者，而无需同时使用洋地黄。
